Titelbild

Partnering

Topas is open to various types of collaboration. The Company plans to partner its proprietary programs at the clinical or pre-clinical stage on an option or a classical licensing basis with biotech or pharmaceutical companies. Topas is also interested in pre-clinical co-development agreements with biotech or academia that have complementary know-how and capabilities. Furthermore, Topas remains open to collaborating with pharmaceutical and biotech companies on selected indications proposed by the respective partner.

Upcoming Events

2nd Antigen-Specific Immune Tolerance Drug Development Summit

Boston/US
March 26-28, 2019

BioEquity Europe 2019

Barcelona/Spain
May 20-21, 2019

2nd TReg Directed Therapies Summit

Boston/US
May 20-22, 2019